HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

Table 5 Immunohistochemical patterns before and after neoadjuvant chemotherapy with docetaxel plus epirubicin in sixty breast cancer patients.

	Pre-chemotherapy N (%)	Post-chemotherapy N (%)	p	Dif. (%)
p53 +	18 (30)	8 (14.5)	0.039	13.2
p21 +	13 (21.6)	5 (9.2)	0.021	14.81
HER-2 +	11 (18.3)	7 (12.5)	0.12	NS

N = number of patients; Dif. = difference between before and after chemotherapy – McNemar test; NS = not significant.

ISSN: 1471-2407